Among the seven studies, two reported advanced or recurrent KRAS-mutant NSCLC [33, 34], three reported stage IV NSCLC [3, 5, 72], one reported stage IV adenocarcinoma [2], and one reported non-specified advanced lung cancer [71]. Here, KRAS is linked to adenocarcinoma.